24 completed. 24 Phase 3, 6 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 24 | Completed 24 |
| Phase 2 | 6 | Completed 6 |
Follow Scleroderma, Diffuse: new trials by email Literature Review of Scleroderma, Diffuse trials Research Report on Scleroderma, Diffuse
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Effectiveness of Cannabinoids on Appetite in Scleroderma CBD oil, Placebo - Systemic Sclerosis, Malnutrition | Phase 3 | Completed | Khon Kaen University | 30 | 2022-11-09 | 2025-02-20 |
| Rituxmab Versus IL-6 in Treating ILD Rituximab, IL6 inhibitor - Interstitial Lung Disease, Scleroderma | Phase 2 / Phase 3 | Completed | Assiut University | 60 | 2021-12-01 | 2023-11-15 |
| Study to Compare the Efficacy of Mycophenolate Mofetil in Systemic Sclerosis Related Early Interstitial Lung Disease Mycophenolate mofetil, Placebo - Systemic Sclerosis, Scleroderma | Phase 3 | Completed | Post Graduate Institute of Medical Education and Research, Chandigarh | 41 | 2016-10-01 | 2018-06-06 |
| Efficacy of Botulinum Toxin In Scleroderma-Associated Raynaud's Syndrome Onabotulinumtoxin A, sterile saline solution - Scleroderma, Raynaud's Syndrome | Phase 3 | Completed | Johns Hopkins University | 40 | 2015-01-01 | 2016-12-22 |
| Rituximab Versus Cyclophosphamide in Connective Tissue Disease-ILD Rituximab, Cyclophosphamide - Interstitial Lung Disease, Scleroderma | Phase 2 / Phase 3 | Completed | Royal Brompton & Harefield NHS Foundation Trust | 104 | 2014-11-01 | 2021-10-07 |
| Gastroesophageal Reflux Treatment in Scleroderma Alginic acid, placebo (for domperidone), Domperidone - Gastroesophageal Reflux Disease, Systemic Sclerosis | Phase 3 | Completed | Khon Kaen University | 80 | 2013-06-01 | 2017-03-27 |
| Rituximab in Systemic Sclerosis Rituximab, Placebo (NaCl) - Systemic Sclerosis | Phase 2 / Phase 3 | Completed | Assistance Publique - Hôpitaux de Paris | 22 | 2013-04-09 | 2025-11-20 |
| Cyclophosphamide Systemic Sclerosis Associated Interstitial Lung Disease Cyclophosphamide, Placebo - Systemic Sclerosis, Scleroderma | Phase 3 | Completed | Assistance Publique - Hôpitaux de Paris | 40 | 2013-01-14 | 2025-09-12 |
| A Trial of Tadalafil in Interstitial Lung Disease of Scleroderma Tadalafil, Placebo - Lung Diseases, Interstitial | Phase 3 | Completed | Sanjay Gandhi Postgraduate Institute of Medical Sciences | 40 | 2012-03-01 | 2015-04-21 |
| Effect of Sildenafil on the Microcirculatory Blood Flow and Endothelial Progenitor Cells in Systemic Sclerosis Sildenafil citrate, Placebo (Sugar pill) - Scleroderma, Systemic, Scleroderma, Diffuse | Phase 3 | Completed | Federal University of São Paulo | 41 | 2011-04-01 | 2016-12-05 |
| Sildenafil Effect on Digital Ulcer Healing in sClerodErma SEDUCE STUDY Sildenafil, placebo - Systemic Scleroderma | Phase 3 | Completed | University Hospital, Lille | 84 | 2010-11-01 | 2026-05-14 |
| A Randomized Control Trial to Assess the Efficacy of Tadalafil in Raynaud's Phenomenon in Scleroderma Tadalafil, Placebo - Raynaud's Phenomenon, Digital Ulcers | Phase 3 | Completed | Sanjay Gandhi Postgraduate Institute of Medical Sciences | 66 | 2009-11-01 | 2010-05-10 |
| Randomised Control Trial to Assess the Efficacy of Tadalafil in Raynaud's Phenomenon in Scleroderma Tadalafil - Raynaud Disease | Phase 3 | Completed | Sanjay Gandhi Postgraduate Institute of Medical Sciences | 25 | 2007-12-01 | 2013-03-22 |
| A Rho-kinase Inhibitor (Fasudil) in the Treatment of Raynaud's Phenomenon Fasudil - Raynaud, Scleroderma | Phase 3 | Completed | Johns Hopkins University | 17 | 2007-04-01 | 2014-11-04 |
| Phase III Study of a Topical Gel Formulation for Treatment and Prevention of Raynaud's Phenomenon Topical AmphiMatrix with nitroglycerin (MQX-503) - Raynaud's Disease, Scleroderma | Phase 3 | Completed | MediQuest Therapeutics | 80 | 2006-12-01 | 2007-05-30 |
| Phase III Study of Topical Gel for Treatment and Prevention of Raynaud's Phenomenon Topical organogel with nitroglycerin - Raynaud's Disease | Phase 3 | Completed | MediQuest Therapeutics | 200 | 2005-12-01 | 2007-08-08 |
| Open-label Study With Bosentan in Interstitial Lung Disease bosentan - Interstitial Lung Disease, Scleroderma | Phase 2 / Phase 3 | Completed | Actelion | 132 | 2004-07-01 | 2025-02-03 |
| Effectiveness and Safety of Lidocaine for Scleroderma Lidocaine 2% without vessel constrictor, Placebo - physiological solution 0,9% - Scleroderma | Phase 2 / Phase 3 | Completed | Federal University of São Paulo | 26 | 2004-04-01 | 2008-08-22 |
| Efficacy and Safety of Oral Bosentan on Healing/Prevention of Digital (Finger) Ulcers in Patients With Scleroderma Bosentan 62.5 mg, Bosentan 125 mg, Placebo - Digital Ulcers, Systemic Sclerosis | Phase 3 | Completed | Actelion | 188 | 2003-10-01 | 2025-02-03 |
| Efficacy and Safety of Oral Bosentan in Pulmonary Fibrosis Associated With Scleroderma Bosentan - Pulmonary Fibrosis, Scleroderma, Systemic | Phase 2 / Phase 3 | Completed | Actelion | 132 | 2003-07-01 | 2025-02-03 |
Showing 20 of 24. Sign in to see all of them.
Scleroderma, Systemic (13) · Raynaud Disease (7) · Lung Diseases, Interstitial (6) · Pulmonary Fibrosis (4) · Autoimmune Diseases (2) · Connective Tissue Diseases (2) · Myositis (2) · Scleroderma, Limited (2) · digital ulcers (2) · Anorexia (1) · Arthritis (1) · Arthritis, Rheumatoid (1) · Dermatomyositis (1) · Dry Eye Syndromes (1)
Skin Diseases (24) · Skin and Connective Tissue Diseases (24) · Connective Tissue Diseases (22) · Scleroderma, Systemic (11) · Lung Diseases (9) · Respiratory Tract Diseases (9) · Cardiovascular Diseases (8) · Vascular Diseases (8) · Embolism and Thrombosis (7) · Livedoid Vasculopathy (7) · Pathological Conditions, Signs and Symptoms (7) · Peripheral Vascular Diseases (7) · Skin Diseases, Vascular (7) · Thrombosis (7) · Pathologic Processes (6)
Bosentan (3) · Cyclophosphamide (3) · Rituximab (3) · Tadalafil (3) · Nitroglycerin (2) · Sildenafil Citrate (2) · Alginic Acid (1) · Botulinum Toxins (1) · Botulinum Toxins, Type A (1) · Domperidone (1) · Lidocaine (1) · Long-Term Synaptic Depression (1) · Mycophenolic Acid (1) · Relaxin (1) · Sodium Chloride (1)
Actelion (3) · Johns Hopkins University (3) · Sanjay Gandhi Postgraduate Institute of Medical Sciences (3) · Assistance Publique - Hôpitaux de Paris (2) · Federal University of São Paulo (2) · Khon Kaen University (2) · MediQuest Therapeutics (2) · Allergan (1) · Assiut University (1) · Encysive Pharmaceuticals (1) · Post Graduate Institute of Medical Education and Research, Chandigarh (1) · Royal Brompton & Harefield NHS Foundation Trust (1) · University Hospital, Lille (1) · University of Medicine and Dentistry of New Jersey (1)
United States (6) · France (3) · India (3) · Brazil (2) · Thailand (2) · United Kingdom (2) · Canada (1) · Egypt (1) · Sweden (1)
Vikas Agarwal, MD, DM (2) · Alexandre WS Silva, PhD (1) · Aman Sharma, MD (1) · Chingching Foocharoen, M.D. (1) · Chingching Foocharoen, MD (1) · Darshan S Bhakuni, MD (1) · Fernando V Andrigueti, MD (1) · Fredrick M Wigley, M.D. (1) · Fredrick M Wigley, MD (1) · James Seibold, MD (1) · Luc Mouthon, MD, PhD (1) · Manal Hassanien, MD (1) · Parasar Ghosh, MD, DM (1)
PMID 33765691, PMID 37929840, PMID 17974598, PMID 20506355, PMID 20805294, PMID 20837499, PMID 25995322, PMID 27179107, PMID 28426903, PMID 28619061, PMID 31813058, PMID 36375479, PMID 41137182